Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciw846 | DOI Listing |
Publication Analysis
Top Keywords
ombitasvir/paritaprevir/ritonavir dasabuvir
8
dasabuvir combination
4
combination treatment
4
treatment patients
4
patients hiv/hcv
4
hiv/hcv co-infection
4
co-infection italian
4
italian compassionate
4
compassionate program
4
program patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!